Maxim Group Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $1
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has initiated coverage on Silexion Therapeutics (NASDAQ:SLXN) with a Buy rating and set a price target of $1.
November 01, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group has initiated coverage on Silexion Therapeutics with a Buy rating and a price target of $1, indicating potential upside.
The initiation of coverage with a Buy rating and a specific price target by Maxim Group is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100